Humacyte director granted 80,000 stock options

Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock.

Rhea-AI Filing Summary

Humacyte, Inc. director Max N. Wallace received a grant of stock options for 80,000 shares of Common Stock. The options carry an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds stock options covering 80,000 underlying shares.

The vesting is time-based: the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments (1/48 of the option) on the 11th of each month through June 11, 2030. This is a compensation-related award, not an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Wallace Max N.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 80,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

Key Figures

Option grant size: 80,000 options Exercise price: $1.08 per share Underlying shares: 80,000 shares +3 more

6 metrics

Option grant size 80,000 options Stock Options (right to buy) granted to director

Exercise price $1.08 per share Conversion or exercise price of granted options

Underlying shares 80,000 shares Common Stock underlying the options

Expiration date June 11, 2036 Option expiration

First vesting date June 11, 2027 25% of options become exercisable

Total options after grant 80,000 options Total stock options held following transaction

Key Terms

Stock Options (right to buy), Grant, award, or other acquisition, Common Stock, exercisable

4 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercisable financial

"The first 25% of the option becomes exercisable on June 11, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Humacyte (HUMA) report for Max N. Wallace?

Humacyte reported that director Max N. Wallace received a grant of 80,000 stock options. These options give him the right to buy Humacyte Common Stock at $1.08 per share as part of his compensation, rather than an open-market trade.

What is the exercise price and term of the new HUMA stock options?

The granted stock options have an exercise price of $1.08 per share and expire on June 11, 2036. This means Wallace can, once vested, buy shares at $1.08 any time before that expiration date, subject to the vesting schedule.

How do the newly granted Humacyte (HUMA) options vest over time?

The first 25% of the option grant becomes exercisable on June 11, 2027. After that, 1/48 of the total option vests on the 11th of each month through June 11, 2030, creating a gradual, time-based vesting pattern.

Is the Humacyte (HUMA) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant of stock options, classified as a grant, award, or other acquisition. It is a compensation-related award, not an open-market stock purchase or sale, and therefore does not directly reflect trading activity in Humacyte shares.

How many Humacyte (HUMA) options does Max N. Wallace hold after this grant?

After the reported transaction, Wallace holds stock options covering 80,000 underlying shares of Humacyte Common Stock. All of these options relate to this grant and will become exercisable over time according to the disclosed vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wallace Max N.

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Max N. Wallace by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)